Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYN-004 for prevention of Clostridium difficile-associated diarrhea in hospitalized patients with lower respiratory tract infection receiving ceftriaxone
2015-002346-32Phase 2Completed
- Sponsor
- Theriva Biologics
- Start
- Oct 2015
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Clostridioides difficile colitis (CDI) and antibiotic-associated diarrhea (AAD) comparing SYN-004 with Placebo (2 arms). Primary endpoint: Percentage of patients with Clostridium difficile-associated diarrhea from Day 1 to 4-week follow-up. Started Oct 2015; status: completed.
02
Drugs
ribaxamase
03
Conditions
Clostridioides difficile colitis (CDI)antibiotic-associated diarrhea (AAD)
Beyond the preview
Go deeper on 2015-002346-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002346-32.